Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma

References

• Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine24(Suppl. 3), S11–S25 (2006).
   Web of Science ®Google Scholar
• Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine24(Suppl. 3), S1–S10 (2006).
   Web of Science ®Google Scholar
• Walboomers JMM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol.189, 12–19 (1999).
   PubMed Web of Science ®Google Scholar
• IARC Monograph Working group. Human papillomaviruses. IARC Press, Lyon, France (2007).
   Google Scholar
• Bosch FX, de Sanjose S. Chapter 1: human papillomavirus and cervical cancer – burden and assessment of causality. J. Natl Cancer Inst. Monogr.31, 3–13 (2003).
   PubMedGoogle Scholar
• De Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology324(1), 17–27 (2004).
   PubMed Web of Science ®Google Scholar
• Munoz N, Bosch FX, de Sanjose S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med.348(6), 518–527 (2003).
   PubMed Web of Science ®Google Scholar
• Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer2(5), 342–350 (2002).
   PubMed Web of Science ®Google Scholar
• Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine24(Suppl. 3), S42–S51 (2006).
   Web of Science ®Google Scholar
• Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat. Rev. Cancer7(1), 11–22 (2007).
   PubMed Web of Science ®Google Scholar
• Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. (Lond.)110(5), 525–541 (2006).
   PubMed Web of Science ®Google Scholar
• Gage JR, Meyers C, Wettstein FO. The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties. J. Virol.64(2), 723–730 (1990).
   PubMed Web of Science ®Google Scholar
• Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science248(4951), 76–79 (1990).
   PubMed Web of Science ®Google Scholar
• Brink AA, Snijders PJ, Meijer CJ. HPV detection methods. Dis. Markers23(4), 273–281 (2007).
   PubMed Web of Science ®Google Scholar
• Evans MF, Cooper K. Human papillomavirus integration: detection by in situ hybridization and potential clinical application. J. Pathol.202(1), 1–4 (2004).
   PubMedGoogle Scholar
• Qureshi MN, Rudelli RD, Tubbs RR, Biscotti CV, Layfield LJ. Role of HPV DNA testing in predicting cervical intraepithelial lesions: comparison of HC HPV and ISH HPV. Diagn. Cytopathol.29(3), 149–155 (2003).
   PubMedGoogle Scholar
• Hesselink AT, van den Brule AJ, Brink AA et al. Comparison of hybrid capture 2 with in situ hybridization for the detection of high-risk human papillomavirus in liquid-based cervical samples. Cancer102(1), 11–18 (2004).
   PubMedGoogle Scholar
• Layfield LJ, Qureshi MN. HPV DNA testing in the triage of atypical squamous cells of undetermined significance (ASCUS): cost comparison of two methods. Diagn. Cytopathol.33(2), 138–143 (2005).
   PubMedGoogle Scholar
• Qureshi MN, Bolick D, Ringer PJ, Spagler FL, Zimmerman G. HPV testing in liquid cytology specimens: comparison of analytic sensitivty and specificity for in situ hybridization and chemiluminescent nucleic acid testing. Acta Cytol.49(2), 120–126 (2005).
   PubMedGoogle Scholar
• Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine24(Suppl. 3), S78–S89 (2006).
   Web of Science ®Google Scholar
• Mayrand MH, Duarte-Franco E, Rodrigues I et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med.357(16), 1579–1588 (2007).
   PubMed Web of Science ®Google Scholar
• Cuzick J, Clavel C, Petry KU et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer119(5), 1095–1101 (2006).
   PubMed Web of Science ®Google Scholar
• Castle PE, Schiffman M, Burk RD et al. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol. Biomarkers Prev.11(11), 1394–1399 (2002).
   PubMed Web of Science ®Google Scholar
• Lie AK, Risberg B, Borge B et al. DNA-versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol. Oncol.97(3), 908–915 (2005).
   PubMed Web of Science ®Google Scholar
• Poljak M, Marin IJ, Seme K, Vince A. Hybrid Capture II HPV test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J. Clin. Virol.25(Suppl. 3), S89–S97 (2002).
   PubMed Web of Science ®Google Scholar
• Klaassen CH, Prinsen CF, de Valk HA, Horrevorts AM, Jeunink MA, Thunnissen FB. DNA microarray format for detection and subtyping of human papillomavirus. J. Clin. Microbiol.42(5), 2152–2160 (2004).
   PubMed Web of Science ®Google Scholar
• Park TC, Kim CJ, Koh YM et al. Human papillomavirus genotyping by the DNA chip in the cervical neoplasia. DNA Cell Biol.23(2), 119–125 (2004).
   PubMedGoogle Scholar
• Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. J. Clin. Microbiol.44(2), 504–512 (2006).
   PubMed Web of Science ®Google Scholar
• Sandri MT, Lentati P, Benini E et al. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J. Clin. Microbiol.44(6), 2141–2146 (2006).
   PubMed Web of Science ®Google Scholar
• Carozzi F, Bisanzi S, Sani C et al. Agreement between the AMPLICOR human papillomavirus test and the hybrid capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease. J. Clin. Microbiol.45(2), 364–369 (2007).
   PubMedGoogle Scholar
• Halfon P, Trepo E, Antoniotti G et al. Prospective evaluation of the hybrid capture 2 and amplicor human papillomavirus (hpv) tests for detection of 13 high-risk hpv genotypes in atypical squamous cells of uncertain significance. J. Clin. Microbiol.45(2), 313–316 (2007).
   PubMed Web of Science ®Google Scholar
• Wahlstrom C, Iftner T, Dillner J, Dillner L. Population-based study of screening test performance indices of three human papillomavirus DNA tests. J. Med. Virol.79(8), 1169–1175 (2007).
   PubMedGoogle Scholar
• Smits HL, van-Gemen B, Schukkink R et al. Application of the NASBA nucleic acid amplification method for the detection of human papillomavirus type 16 E6-E7 transcripts. J. Virol. Methods54(1), 75–81 (1995).
   PubMedGoogle Scholar
• Sotlar K, Stubner A, Diemer D et al. Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. J. Med. Virol.74(1), 107–116 (2004).
   PubMed Web of Science ®Google Scholar
• Molden T, Kraus I, Skomedal H, Nordstrom T, Karlsen F. PreTect HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses. J. Virol. Methods142(1–2), 204–212 (2007).
   PubMed Web of Science ®Google Scholar
• Castle PE, Dockter J, Giachetti C et al. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin. Cancer Res.13(9), 2599–2605 (2007).
   PubMed Web of Science ®Google Scholar
• Wang-Johanning F, Lu DW, Wang Y, Johnson MR, Johanning GL. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis. Cancer94(8), 2199–2210 (2002).
   PubMed Web of Science ®Google Scholar
• Molden T, Kraus I, Karlsen F, Skomedal H, Nygard JF, Hagmar B. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol. Biomarkers Prev.14(2), 367–372 (2005).
   PubMed Web of Science ®Google Scholar
• Molden T, Nygard JF, Kraus I et al. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int. J. Cancer114(6), 973–976 (2005).
   PubMed Web of Science ®Google Scholar
• Molden T, Kraus I, Karlsen F, Skomedal H, Hagmar B. Human papillomavirus E6/E7 mRNA expression in women younger than 30 years of age. Gynecol. Oncol.100(1), 95–100 (2006).
   PubMed Web of Science ®Google Scholar
• Kraus I, Molden T, Erno LE, Skomedal H, Karlsen F, Hagmar B. Human papillomavirus oncogenic expression in the dysplastic portio; an investigation of biopsies from 190 cervical cones. Br. J. Cancer90(7), 1407–1413 (2004).
   PubMed Web of Science ®Google Scholar
• Kraus I, Molden T, Holm R et al. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J. Clin. Microbiol.44(4), 1310–1317 (2006).
   PubMed Web of Science ®Google Scholar
• Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific DNA and RNA persistence – implications for cervical disease progression and monitoring. J. Med. Virol.73(1), 65–70 (2004).
   PubMed Web of Science ®Google Scholar
• Sherman ME, Schiffman M, Cox JT. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J. Natl Cancer Inst.94(2), 102–107 (2002).
   PubMed Web of Science ®Google Scholar
• ASCUS-LSIL Traige Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am. J. Obstet. Gynecol.188(6), 1383–1392 (2003).
   PubMed Web of Science ®Google Scholar
• Cuzick J, Szarewski A, Cubie H et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet362(9399), 1871–1876 (2003).
   PubMed Web of Science ®Google Scholar
• Naucler P, Ryd W, Tornberg S et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med.357(16), 1589–1597 (2007).
   PubMed Web of Science ®Google Scholar
• Bulkmans NW, Berkhof J, Rozendaal L et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet370(9601), 1764–1772 (2007).
   PubMed Web of Science ®Google Scholar
• Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol. Oncol.104(1), 232–246 (2007).
   PubMed Web of Science ®Google Scholar
• Davies P, Arbyn M, Dillner J et al. A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. Int. J. Cancer118(4), 791–796 (2006).
   PubMedGoogle Scholar
• Naucler P, Ryd W, Tornberg S et al. HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br. J. Cancer97(1), 129–132 (2007).
   PubMed Web of Science ®Google Scholar
• Nanda K, McCrory DC, Myers ER et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann. Intern. Med.132(10), 810–819 (2000).
   PubMed Web of Science ®Google Scholar
• Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet. Gynecol.111(1), 167–177 (2008).
   PubMedGoogle Scholar
• Meijer CJ, Snijders PJ, Castle PE. Clinical utility of HPV genotyping. Gynecol. Oncol.103(1), 12–17 (2006).
   PubMedGoogle Scholar
• Bulkmans NW, Rozendaal L, Snijders PJ et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int. J. Cancer110(1), 94–101 (2004).
   PubMed Web of Science ®Google Scholar
• Kitchener HC, Almonte M, Wheeler P et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br. J. Cancer95(1), 56–61 (2006).
   PubMed Web of Science ®Google Scholar
• Jakobsson M, Gissler M, Sainio S, Paavonen J, Tapper AM. Preterm delivery after surgical treatment for cervical intraepithelial neoplasia. Obstet. Gynecol.109(2 Pt 1), 309–313 (2007).
   PubMed Web of Science ®Google Scholar
• Sjoborg KD, Vistad I, Myhr SS et al. Pregnancy outcome after cervical cone excision: a case-control study. Acta Obstet. Gynecol. Scand.86(4), 423–428 (2007).
   PubMed Web of Science ®Google Scholar
• Nohr B, Tabor A, Frederiksen K, Kjaer SK. Loop electrosurgical excision of the cervix and the subsequent risk of preterm delivery. Acta Obstet. Gynecol. Scand.86(5), 596–603 (2007).
   PubMed Web of Science ®Google Scholar
• Bruinsma F, Lumley J, Tan J, Quinn M. Precancerous changes in the cervix and risk of subsequent preterm birth. BJOG114(1), 70–80 (2007).
   PubMed Web of Science ®Google Scholar
• Ratman S, Coutlee F, Bentley J et al. HPV E6/E7 mRNA testing in cervical cancer screening: preliminary results from a multicenter Canadian study. Presented at: 24th International Papillomavirus Conference. Beijing, China, November 3–9 (2007) (Abstract).
   Google Scholar
• Trope A, Sjoborg KD, Eriksen T et al. Comparison of HPV DNA- and RNA-testing in women with cervical neoplasia. Presented at: 24th International Papillomavirus Conference. Beijing, China, November 3–9 (2007) (Abstract).
   Google Scholar
• Smith JS, Lindsay L, Hoots B et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer121(3), 621–632 (2007).
   PubMed Web of Science ®Google Scholar
• Schiffman M, Khan MJ, Solomon D et al. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J. Natl Cancer Inst.97(2), 147–150 (2005).
   PubMed Web of Science ®Google Scholar
• Andersson S, Hansson B, Norman I et al. Expression of E6/E7 mRNA from ‘high risk’ human papillomavirus in relation to CIN grade, viral load and p16INK4a. Int. J. Oncol.29(3), 705–711 (2006).
   PubMed Web of Science ®Google Scholar